13F Pro Quality Score

53.4/100

Rank #1,286 of 2,879 stocksTOP 50%

View Consumer Staples peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

10.2/100

Profitability

77.4/100

Balance Sheet

87.7/100

Earnings Quality

99.8/100

Free Cash Flow

38.8/100

Institutional Flow

24.4/100

Revenue Scale

56.4/100

Dilution Risk

45.0/100

NUS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NU SKIN ENTERPRISES, INC. (NUS), a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores NUS at 53.4/100 on a 32-signal composite quality model, placing it at rank #1,286 of 2,879 stocks — the top half of the AI-ranked universe. NUS scores in the top quartile across earnings quality (99.8), balance sheet strength (87.7), profitability (77.4). Areas of concern include revenue growth (10.2) and institutional flow (24.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 45.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), NU SKIN ENTERPRISES, INC. reports quarterly revenue of $320.6M, net income of $1.8M, free cash flow of $-17.6M. Top institutional holders of NUS by reported 13-F value include BlackRock,, CHARLES SCHWAB INVESTMENT MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NUS trades on the NYSE exchange and files with the SEC under CIK 1021561. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NU SKIN ENTERPRISES, INC. directly from SEC EDGAR. NU SKIN ENTERPRISES, INC.'s 13F Pro composite quality score has ranged between 8 and 58 since 2021, currently 53.4 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$320.6M

Net Income

Q1 2026

$1.8M

Free Cash Flow

Q1 2026

$-17.6M

D/E Ratio

Q1 2026

0.28

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-14.3% YoY
$1.49BFY 2025
FY22 $2.23BFY23 $1.97BFY24 $1.73BFY25 $1.49B

Net Income

+209.3% YoY
$160.2MFY 2025
FY22 $104.8MFY23 $8.6MFY24 $-146.6MFY25 $160.2M

Operating Income

+143.4% YoY
$65.8MFY 2025
FY22 $110.8MFY23 $48.3MFY24 $-151.6MFY25 $65.8M

EPS (Diluted)

+207.8% YoY
$3.18FY 2025
FY22 $2.07FY23 $0.17FY24 $-2.95FY25 $3.18

Total Assets

-4.3% YoY
$1.41BFY 2025
FY22 $1.82BFY23 $1.81BFY24 $1.47BFY25 $1.41B

Total Debt

-43.0% YoY
$224.2MFY 2025
FY22 $402.5MFY23 $503.0MFY24 $393.6MFY25 $224.2M

Op. Cash Flow

-28.2% YoY
$80.3MFY 2025
FY22 $108.1MFY23 $118.6MFY24 $111.7MFY25 $80.3M

AI Insight: NUS Financial Trends

Debt cut nearly in half since Q2 2024, but revenue has declined six consecutive quarters to a multi-period low of $321M in Q1 2026.

Total debt fell sharply from $458M in Q2 2024 to $224M in Q1 2026, a 51% reduction over seven quarters.

Equity has gradually strengthened from $686M in Q2 2024 to $805M in Q4 2025, though it dipped to $794M in Q1 2026.

Revenue has declined from $446M in Q4 2024 to $321M in Q1 2026, the lowest level in the dataset.

Operating income turned positive in Q2 2025 ($31M) after three quarters of losses, but compressed to just $4M in Q1 2026.

Operating cash flow turned negative at -$4M in Q1 2026, the first negative reading in the dataset — a key deterioration signal.

Q1 2025 net income of $108M appears anomalous versus surrounding quarters; likely driven by a non-recurring item, not operating momentum.

Revenue contraction accelerating — Q1 2026 at $321M is 17% below Q2 2024; stabilization needed to validate balance-sheet progress.

AI Insight: NUS Ratio Trends

Nu Skin has stabilized after catastrophic losses in Q2 and Q4 2024, but Q1 2026 profitability collapsed to near-zero, raising doubts about sustainability.

Operating margin swung from -28.6% in Q2 2024 to a recovery range of 5.9%–8.0% across Q3 2025–Q2 2025, then fell sharply to 1.3% in Q1 2026.

Leverage improved materially: D/E declined from 0.67 in Q2 2024 to 0.28 by Q4 2025 and held at 0.28 in Q1 2026.

ROIC turned positive and reached 11.9% in Q2 2025 but has decelerated steadily to 1.6% in Q1 2026.

Q1 2026 NPM dropped to 0.6% from 3.9% in Q4 2025 — monitor whether this reflects seasonal weakness or renewed structural deterioration.

Recurring large negative quarters (Q2 2024, Q4 2024) suggest potential for impairment or restructuring charges; watch Q2 2026 closely.

Get alerted when NUS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NU SKIN ENTERPRISES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put NUS on your watchlist

Track score changes the day NU SKIN ENTERPRISES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is NUS a good stock to buy?

13F Pro's AI-powered analysis of NU SKIN ENTERPRISES, INC. (NUS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NUS are available on the NUS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NUS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NUS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NU SKIN ENTERPRISES, INC.'s investment landscape.